GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coherus Oncology Inc (NAS:CHRS) » Definitions » Net Margin %

CHRS (Coherus Oncology) Net Margin % : -744.43% (As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is Coherus Oncology Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Coherus Oncology's Net Income for the three months ended in Mar. 2025 was $-56.6 Mil. Coherus Oncology's Revenue for the three months ended in Mar. 2025 was $7.6 Mil. Therefore, Coherus Oncology's net margin for the quarter that ended in Mar. 2025 was -744.43%.

The historical rank and industry rank for Coherus Oncology's Net Margin % or its related term are showing as below:

CHRS' s Net Margin % Range Over the Past 10 Years
Min: -15306.56   Med: -87.92   Max: 27.79
Current: -66.3


CHRS's Net Margin % is ranked better than
54.59% of 980 companies
in the Biotechnology industry
Industry Median: -107.785 vs CHRS: -66.30

Coherus Oncology Net Margin % Historical Data

The historical data trend for Coherus Oncology's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coherus Oncology Net Margin % Chart

Coherus Oncology Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.79 -87.92 -138.24 -92.48 10.68

Coherus Oncology Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,457.32 -19.88 -15.19 -93.63 -744.43

Competitive Comparison of Coherus Oncology's Net Margin %

For the Biotechnology subindustry, Coherus Oncology's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coherus Oncology's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coherus Oncology's Net Margin % distribution charts can be found below:

* The bar in red indicates where Coherus Oncology's Net Margin % falls into.


;
;

Coherus Oncology Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Coherus Oncology's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as

Net Margin=Net Income (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=28.507/266.96
=10.68 %

Coherus Oncology's Net Margin for the quarter that ended in Mar. 2025 is calculated as

Net Margin=Net Income (Q: Mar. 2025 )/Revenue (Q: Mar. 2025 )
=-56.569/7.599
=-744.43 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Coherus Oncology  (NAS:CHRS) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Coherus Oncology Net Margin % Related Terms

Thank you for viewing the detailed overview of Coherus Oncology's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Coherus Oncology Business Description

Traded in Other Exchanges
Address
333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline which includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer.
Executives
Mats Wahlstrom director 500 GOLDEN RIDGE ROAD, SUITE 100, GOLDEN CO 80401
Dennis M Lanfear director, officer: President and CEO C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Michael Lee Ryan director C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Mcdavid Stilwell officer: Chief Financial Officer C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Bryan J Mcmichael officer: See Remarks C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, REDWOOD CITY CA 94065
Paul Reider officer: Chief Commercial Officer C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Jill O'donnell-tormey director C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Charles W. Newton director 46 FREDRICK AVENUE, ATHERTON CA 94027
Lee Nisley Newcomer director 264 BUSHAWAY ROAD, WAYZATA MN 55391-1901
James Healy director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Vladimir Vexler officer: Chief Scientific Officer 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Vincent R Anicetti officer: Chief, Quality & Compliance COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Jean-frederic Viret officer: Chief Financial Officer ANESIVA, INC., 650 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Mark Stolper director 150 COTNER AVENUE, LOS ANGELES CA 90025
Alan C Mendelson director ALAN C MENDELSON, 135 COMMONWEALTH DR, MENLO PARK CA 94025